Immunocore Holdings (IMCR) Cash from Financing Activities (2023 - 2026)

Immunocore Holdings has disclosed Cash from Financing Activities across 4 years of filings, most recently posting $656000.0 for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $656000.0, down 74.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.5 million (up 121.13% YoY), and the FY2025 annual result was $12.4 million, down 96.4% from the prior year.
• Cash from Financing Activities came in at $656000.0 for Q1 2026 at Immunocore Holdings, down from $4.3 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $396.0 million in Q1 2024 to a low of -$51.5 million in Q4 2024.
• The 4-year median for Cash from Financing Activities is $3.7 million (2025), against an average of $30.1 million.
• Peak annual rise in Cash from Financing Activities reached 6350.76% in 2024, while the deepest fall reached 923.65% in 2024.
• Immunocore Holdings' Cash from Financing Activities stood at $6.3 million in 2023, then plunged by 923.65% to -$51.5 million in 2024, then soared by 108.32% to $4.3 million in 2025, then tumbled by 84.69% to $656000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $656000.0 (Q1 2026), $4.3 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.